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Abstract
This is a bloodless book, literally and figuratively. It is bloodless in the sense that it excludes from its frame the
cancer patients whose blood and tumors are the central physical materials of the high technoscience described
here. And it is bloodless in the sense that it deals with a pressing moral issue—how some forms of cancer
research become public and scientific priorities—without a moral perspective. This divorce from human need
and vulnerability necessarily precludes consideration of the book as a work of history.
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 ment funding determine their interpretation.
 Their names change according to which interest
 group is uppermost, a nominalism that even John
 Locke would not have recognized. Hematologi-
 cal disease, it turns out, is like Gertrude Stein's
 description of Oakland, California: when you get
 there, "there is no there there."
 Wailoo's is a highly original way of writing
 history. You could call it interpretive narrative.
 Wailoo sticks to the most classical of sources,
 such as published accounts in medical journals,
 and builds up a detailed, periodized story of each
 disease and its technologies and treatments.
 Moral management, liver extract, splenec-
 tomy-he slots them into the complex situations
 of their day in a way that allows us to understand
 the persuasiveness of their theoretical basis and
 the short-lived success of the therapy based on
 it. We can learn much, he says, by studying tech-
 nologies, and treatments, that have not survived.
 Wailoo's most striking story concerns the
 linkup between the test for sickling and the sup-
 posed inheritance of sickle-cell anemia as a
 Mendelian dominant. The detection of this
 symptomless trait in about 10 percent of Blacks
 allowed white physicians of the 1930s and 1940s
 to claim that sickling was a latent disease of Ne-
 groes and a marker for the detection of Negro
 blood. It not only marked Blacks as sickly but
 suggested that cases found in non-Blacks indi-
 cated hidden "black blood" in a family. The rac-
 ist ideology that condemned miscegenation
 could point to sickle-cell anemia as an example
 of the dangers of allowing the Negro access to
 white society. By the 1950s and 1960s, the em-
 phasis on the trait as a racial stigma was begin-
 ning to give way to the painful "sickling crisis"
 as a source of suffering in affected children. As
 scientific racism receded, it turned out that the
 trait was a recessive, not a dominant, and that
 only if a child inherited it from both parents
 would he or she be symptomatic. Ironically, that
 finding implied that miscegenation should be en-
 couraged as a preventive measure. In addition,
 the newer technique of electrophoresis showed
 that there were many different abnormal hemo-
 globins, scattered throughout human popula-
 tions. Their presence did not necessarily cause
 any problem. As the historian Owsei Temkin
 wrote in 1963, "Danger arises lest specific dis-
 eases be postulated which have no clinical real-
 ity." It is a danger that today's searchers for de-
 fects of the human genome might bear in mind.
 Wailoo's cross-linkages between diagnosis,
 technology, professional and commercial inter-
 ests, and the rise and fall of ideological tides
 make his work a very stimulating, insightful
.  book. It is, in addition, well written and a plea-
 sure to read. Not only that, individual chapters
 have a stand-alone structure that will make them
 ideal for "readings" and discussion. I foresee that
 Wailoo's book will be a very successful text, one
 that will have a good influence on the field.
 PAULINE M. H. MAZUMDAR
 Joan H. Fujimura. Crafting Science: A Socio-
 history of the Quest for the Genetics of Cancer.
 xii + 322 pp., illus., bibl., index. Cambridge,
 Mass./London: Harvard University Press, 1996.
 $45.
 This is a bloodless book, literally and figura-
 tively. It is bloodless in the sense that it excludes
 from its frame the cancer patients whose blood
 and tumors are the central physical materials of
 the high technoscience described here. And it is
 bloodless in the sense that it deals with a press-
 ing moral issue-how some forms of cancer re-
 search become public and scientific priorities-
 without a moral perspective. This divorce from
 human need and vulnerability necessarily pre-
 cludes consideration of the book as a work of
 history.
 Joan Fujimura explores the rise of the proto-
 oncogene theory in the 1970s and 1980s. She
 considers the experimental systems that re-
 s a chers used, the genetic technologies they
 employed, the arguments that guided their the-
 ories, and the kinds of problems this package of
 technology and theory solved. Her goal is to pull
 apart the processes involved in the making of
 theories and facts, with proto-oncogenes serving
 as a case study.
 Proto-oncogenes are normal human genes that
 resemble genes in viruses that cause cancer in
 laboratory organisms. The theory that they could
 be triggered to produce human cancers was ac-
 cepted by the scientific community by the late
 1980s. The theory was novel in that it found the
 cause of cancer in normal genes. It was success-
 ful in the sense that it could be used to bring
 chemical carcinogenesis, radiation effects, tumor
 progression, and other phenomena under a single
 umbrella. It was successful too in the sense that
 it attracted funding agencies and was recognized
 within the scientific community as an appropri-
 ate part of grant applications. It involved mate-
 rials that could produce relatively rapid results,
 and it created manageable problems.
 Fujimura tells the story of scientific interpre-
 tations of the proto-oncogene by following what
 she calls traces of continuity, distributed author-
 ity, co-construction, theory-methods packages,
i , i  addition, we l wri ten and a plea-
. ot only that, individual chapters
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 articulation work, and doability. There is no lin-
 ear narrative, a form she explicitly rejects. There
 are some interesting observations and sugges-
 tions. Fujimura, for example, explores how the
 analytical place of biological materials can
 change: the tumor-causing virus served as the
 focus of a major research program in the 1970s,
 then, after 1980, shifted to become a technology
 for the exploration of a different biological en-
 tity, the proto-oncogene. She also maps negoti-
 ations across disciplines, institutions, and lines
 of research. The part I found most compelling
 was her discussion of those researchers who re-
 fused to be enrolled and resisted the "band-
 wagon."
 Fujimura's methods and language are broadly
 sociological, and her writing style tends to be
 dense. She identifies herself as a proponent of
 actor-network theory, although she also employs
 many other frames. She considers disciplinary
 constraints inherently limiting. The book might
 therefore be understood as an exploration of
 what it would mean to study science without
 standing in any particular spot on the scholarly
 map.
 SUSAN LINDEE
 Ilana Lowy. Between Bench and Bedside: Sci-
 ence, Healing, and Interleukin-2 in a Cancer
 Ward. viii + 370 pp., illus., index. Cambridge,
 Mass./London: Harvard University Press, 1996.
 $39.95.
 Ilana Lowy, a senior researcher with INSERM
 in Paris, is a triple threat in the field of science
 studies: she is a historian of science who initially
 trained as an immunologist, and through her
 work she has gained sociological expertise, par-
 ticularly in ethnographic research. She is, in ad-
 dition, an excellent writer. In Between Bench and
 Bedside, she provides a rich analytic and de-
 scriptive study of the interplay between the
 worlds of basic biomedical and clinical research
 in the "war" against cancer. The initial focus of
 her research was a firsthand study of clinical tri-
 als of interleukin-2 (IL-2) at the Cancer Foun-
 dation in Paris. IL-2, first identified by immu-
 nologists in 1976, is a protein secreted by white
 blood cells that subsequent research showed to
 be a nonspecific stimulator of the immune sys-
 tem. The IL-2 molecule, Lowy states, "was im-
 mediately perceived as having important thera-
 peutic potential" for immune deficiency
 conditions, including the type often seen in ad-
 vanced cancer. When the IL-2 gene was cloned
 in 1983, research groups, biotechnology and
 r , and doability. There is no lin-
i , a for  she explicitly rejects. There
i esting observations and su ges-
ji a, for exa ple, explores how the
 pharmaceutical companies, and the media rap-
 idly pronounced it the newest experimental an-
 ticancer "miracle drug," "a natural weapon
 against cancer." Early human trials in the United
 States, however, indicated that IL-2 was more
 toxic than expected, and the "clinical results in
 cancer patients were not very impressive."
 Despite these results, many leading cancer
 centers in the United States and Europe launched
 clinical trials of IL-2 between 1985 and 1990,
 one of which was the Cancer Foundation re-
 search that Lowy observed from November 1986
 until July 1990.
 In response to the results of the trials that had
 been conducted by the time the Cancer Foun-
 dation's trial began, the scope of Lowy's re-
 search, and the eventual contents of the book,
 broadened, for she became intrigued by the ques-
 tion of why the trial was being conducted, as well
 as how. This question led her to explore and em-
 bed the IL-2 trial in a broader historical and so-
 ci logical context: the development of a distinc-
 tive culture of clinical experimentation in
 oncology; the scientific and social history of can-
 cer immunotherapy from the 1890s through the
 1980s; and the interrelationships among the sci-
 entific, medical, and sociopolitical cultures of
 the Cancer Foundation itself.
 In the end Lowy found that the Cancer Foun-
 dation trial "turned out to be a different enter-
 prise from the one [she] had expected to follow."
 But the actual nature and outcomes of the trial
 itself, and the issues it led her to consider, gen-
 erated an absorbing study. I was particularly
 struck by her account of the relationships be-
 tween basic and clinical research-the interplay
 between bench and bedside-in the IL-2 trial.
 "One of the trial's main declared goals," Lowy
 notes, "was the demonstration of smooth and
 fruitful collaboration between scientists and phy-
 sicians" in the immunology and hematology labs
 and the oncology clinic. There was, indeed, col-
 laboration between the lab and the clinic, which
 Lowy ascribes to the "science-laden" develop-
 ment of orthodox cancer therapy. But despite the
 mention of "cancer ward" in the subtitle of the
 book, Lowy's observational work, and thus most
 of her analysis, was confined to the laboratory.
 The Cancer Foundation's labs and oncology
 wards were separated not only by actual physical
 walls but by many nonmaterial barriers as well-
 not least among them the fearful reluctance of
 the scientists, and the observer herself, to leave
 the confines of the laboratory and enter the world
 of the desperately ill cancer patients and the phy-
 sician-investigators studying the effects of IL-2
 on them and their disease. If there is an element
aceutical companies, and the media rap-
 ronounced it the newest experimental n-
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